<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01975493</url>
  </required_header>
  <id_info>
    <org_study_id>13.0095</org_study_id>
    <secondary_id>2013-002366-40</secondary_id>
    <secondary_id>13/LO/0907</secondary_id>
    <nct_id>NCT01975493</nct_id>
  </id_info>
  <brief_title>Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study</brief_title>
  <acronym>NAPPA</acronym>
  <official_title>Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of NAPPA is to develop new models to improve our understanding of how children
      process ('metabolise') penicillins, to help us discover if we can improve the dosing
      regimens used for children in the future. The study population will involve children and
      neonates who need a penicillin antibiotic as part of their normal National Health Service
      (NHS) care, and who also need blood tests or intravenous access. Therefore the antibiotic
      study can be done without the need for any extra invasive procedures, and there will be no
      change to the medication therapy received by participants. In addition, NAPPA will evaluate
      whether it is feasible to measure antibiotic levels on a tiny drop of blood put onto
      absorbent paper (&quot;dried blood spot&quot;). This allows the sample to be stored and tested later
      on. NAPPA will compare the level of the antibiotic using this method with the level measured
      in the usual way, to show if this is a reliable method that could be used routinely in the
      future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The pharmacokinetic parameters of drug clearance and volume of distribution for each penicillin.</measure>
    <time_frame>Participants will be followed for the duration of enrolment, an expected average of 7 days.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Paediatric Antimicrobial Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ampicillin</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzylpenicillin</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-amoxiclav</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flucloxacillin</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin/tazobactam</arm_group_label>
    <description>Group subdivided into age categories:
Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples and dried blood spots to be retained for retrospective analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children (aged under 16 years) and infants (including both full-term and premature
        neonates), admitted to hospital and routinely prescribed one (or more) of the study
        penicillins according to local hospital policy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Child aged under 16 years receiving one of the specified penicillins and with
             intravenous access or blood test(s) as part of their routine clinical care.

          -  Informed consent form signed by parent or legal guardian.

        Exclusion Criteria:

          -  Any child or infant unlikely to survive 48 hours after recruitment.

          -  Patient known to be pregnant.

          -  Known allergy or hypersensitivity to beta-lactam antibiotics (including penicillins
             and cephalosporins) or beta-lactamase inhibitors.

          -  Patient receiving (or planned to receive) haemofiltration, haemodialysis, peritoneal
             dialysis, extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sharland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatiana Munera Huertas, PhD</last_name>
    <phone>+442087255382</phone>
    <email>tmunerah@sgul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Barker, BM BCh</last_name>
    <phone>+442087255382</phone>
    <email>cbarker@sgul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prakash Satodia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liverpool Women's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L8 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Turner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Riordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mike Sharland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nigel Klein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina Children's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Esse Menson, MB BS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Anthony, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tim Scorrer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.grip-network.org/index.php/cms/en/home</url>
    <description>Global Research in Paediatrics (GRiP)</description>
  </link>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infectious Diseases</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Neonatology</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Antimicrobials</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
